Search This Blog

Tuesday, January 2, 2024

atai: Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

 EMP-01 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose dependent. There were no study discontinuations, and no serious or severe AEs were observed in the study. Non-clinically significant increases in blood pressure and heart rate were observed, though such changes showed limited dose dependency. Further, the peak body temperatures observed fell within the normal range. Finally, bruxism was observed in only 1 of 24 subjects that received EMP-01.

The PK profile of EMP-01 was dose-proportional. The PD measures included both subjective reports and blood-based biomarkers. Significant, consistent and dose-dependent changes were seen on several of these exploratory PD measures. EMP-01 administration resulted in a differentiated subjective experience compared to racemic MDMA on standard psychedelic experience questionnaires. Further, dose dependent changes on measures of emotional breakthrough, a phenomenon thought to be a key mediator of the long-term psychological changes associated with psychedelics, were noted in this healthy volunteer population.

Detailed clinical data from the Phase 1 study of EMP-01 are expected to be presented at a future medical meeting.

https://www.globenewswire.com/news-release/2024/01/02/2802639/0/en/atai-Life-Sciences-Announces-Positive-Topline-Results-from-Single-Ascending-Dose-Phase-1-Study-with-EMP-01-R-MDMA.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.